Cisapride (R 51619): Dual-Action Probe for Cardiac Electrophysiology and 5-HT4 Receptor Signaling

Executive Summary: Cisapride (R 51619) acts as a nonselective 5-HT4 receptor agonist and a potent inhibitor of the human ether-à-go-go-related gene (hERG) potassium channel, with well-characterized effects on cardiac electrophysiology (Grafton et al., 2021). It is used in phenotypic screening platforms—including deep learning with iPSC-derived cardiomyocytes—to assess cardiotoxicity and arrhythmogenic potential. The compound is chemically stable as a solid at -20°C and is provided by APExBIO at ≥99.70% purity with full quality control data (APExBIO). Cisapride enables robust modeling of 5-HT4 signaling and hERG channel inhibition in both cardiac and gastrointestinal motility research. Its integration into high-content screening workflows supports de-risking in early drug discovery.

Biological Rationale

Cisapride (R 51619) is a synthetic small molecule designed to interrogate serotonergic signaling and cardiac repolarization mechanisms. The 5-HT4 receptor is expressed in cardiac tissues and the gastrointestinal tract, modulating cAMP production and downstream signaling cascades. Abnormalities in hERG channel function are a leading cause of drug-induced long QT syndrome and arrhythmias (Grafton et al., 2021). Cisapride’s dual activity allows for the selective study of 5-HT4-mediated pathways and direct assessment of hERG channel blockade. These features make it essential for basic research and for validating preclinical drug safety models. The compound has also been adopted in computational and high-throughput phenotypic screening to benchmark cardiotoxicity risks in candidate molecules.

Mechanism of Action of Cisapride (R 51619)

Cisapride is a nonselective agonist at 5-HT4 receptors, which are G protein-coupled receptors linked to Gs proteins. Activation elevates intracellular cAMP, modulating ion channel activity and contractility in both cardiac and gastrointestinal tissues. Concurrently, Cisapride is a potent inhibitor of the hERG (KCNH2) potassium channel, with nanomolar affinity in patch-clamp studies (Grafton et al., 2021). hERG channel blockade impairs cardiac repolarization, manifesting as QT interval prolongation. The compound does not discriminate between 5-HT4 receptor subtypes, earning its designation as a nonselective agonist. Its mechanism underpins its use as a tool for dissecting arrhythmogenic mechanisms and serotonergic modulation in vitro.

Evidence & Benchmarks

• Cisapride exhibits high-affinity inhibition of the hERG channel in iPSC-derived cardiomyocytes, producing QT-prolongation phenotypes measurable by deep learning-enabled image analysis (Grafton et al., 2021).
• In high-content screening, Cisapride induced dose-dependent cardiotoxicity, distinguishable from DNA intercalators and kinase inhibitors, validating its use as an ion channel blocker reference (Grafton et al., 2021).
• Cisapride’s solid form is chemically stable at -20°C; it is soluble at ≥23.3 mg/mL in DMSO and at ≥3.47 mg/mL in ethanol, but insoluble in water (APExBIO).
• APExBIO supplies Cisapride (SKU B1198) with ≥99.70% purity, confirmed by HPLC, NMR, and MSDS documentation (APExBIO).
• Phenotypic assays using iPSC-derived cardiomyocytes and Cisapride enable early-stage de-risking in drug development pipelines due to rapid, scalable detection of cardiotoxicity (Grafton et al., 2021).

Applications, Limits & Misconceptions

Cisapride is primarily used in scientific research to study:

• Cardiac electrophysiology and arrhythmia mechanisms, via hERG channel inhibition.
• 5-HT4 receptor-mediated signaling pathways in both cardiac and gastrointestinal contexts.
• High-content phenotypic screening for cardiotoxicity using deep learning and iPSC-derived cardiomyocytes.
• De-risking early drug discovery by benchmarking ion channel-related liabilities.

For a discussion of the compound’s application in high-content screening and deep learning-based cardiotoxicity modeling, see this related article, which this page extends by providing updated product parameters and direct evidence links.

This article further clarifies mechanistic applications compared to existing guidance by anchoring claims in recent high-throughput screening literature and specifying physicochemical handling guidelines.

Common Pitfalls or Misconceptions

• Not selective for 5-HT4 subtypes: Cisapride activates all 5-HT4 receptor isoforms, limiting its use for subtype-specific studies.
• Not water-soluble: Insoluble in water; dissolution requires DMSO or ethanol at specified concentrations.
• Long-term solution storage instability: Stock solutions degrade over time; only solid form is recommended for extended storage at -20°C.
• Not a clinical therapeutic: Use is restricted to research; Cisapride is not approved for clinical use in most jurisdictions due to cardiac safety concerns.
• Potential off-target effects: At high concentrations, may interact with other ion channels or receptors.

Workflow Integration & Parameters

Cisapride (R 51619), as supplied by APExBIO, is provided as a solid with ≥99.70% purity. For cell-based assays, dissolution should be performed in DMSO (≥23.3 mg/mL) or ethanol (≥3.47 mg/mL). Water is not a suitable solvent. Storage at -20°C maintains stability; avoid freeze-thaw cycles. Stock solutions should be freshly prepared before use to ensure biological activity. For high-content phenotypic screening, concentrations between 10 nM and 10 μM are commonly used in iPSC-cardiomyocyte models (Grafton et al., 2021). Integration with deep learning image analysis allows for unbiased detection of cardiotoxic phenotypes, supporting robust pipeline de-risking. For further hands-on workflow guidance and troubleshooting, see this scenario-driven protocol, which this article updates by including current quality specifications and evidence links.

Conclusion & Outlook

Cisapride (R 51619) is a validated tool compound for dissecting 5-HT4 receptor signaling and modeling hERG channel-related cardiac risk. Its dual action underpins its value in preclinical testing, high-throughput screening, and translational research. APExBIO’s high-purity offering ensures reproducibility and regulatory compliance. As in vitro models and phenotypic screening evolve, Cisapride will remain integral for benchmarking and de-risking drug candidates in cardiac and gastrointestinal research. For detailed product specifications, refer to the official product page.